FANCD2 and pancreatic adenocarcinoma: Moreover, we first discovered and validated FANCD2 was a promising biomarker and could be an effective for prognostic recognition, immune efficacy evaluation, and mRNA vaccine for patients with PAAD, providing a vital guidance for further study of the correlation between FANCD2 and PD-L1 on mRNA vaccine and personalized immunotherapy.